Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., . . . Denmeade, S. R. (2007). Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint.

Collins, Connie, Michael A. Carducci, Mario A. Eisenberger, John T. Isaacs, Alan W. Partin, Roberto Pili, Victoria J. Sinibaldi, Janet S. Walczak, a Samuel R. Denmeade. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.

Collins, Connie, et al. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.